Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study
Creators
- 1. Robert Koch Institute, Berlin, Germany
- 2. Infinity, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France
Contributors
- 1. Robert Koch Institute, Berlin, Germany
- 2. Navrongo Health Research Centre and Research Laboratory, Navrongo, Ghana
- 3. PATH, Seattle, Washington, USA
- 4. National Institute of Research on Public Health (INRSP), Bamako, Mali
Description
The data represent the concentrations of specific neutralizing antibodies following infant immunization against yellow fever. We used a microneutralization assay to measure protective antibodies against yellow fever virus in 587 Malian and 436 Ghanaian children vaccinated around age 9 months, and followed for 4.5 years (Mali), or 2.5 and 6 years (Ghana). We standardized antibody concentrations with reference to the yellow fever WHO International Standard.
The serum samples used in this study, and the sample metadata included in the present dataset originate from trials of the meningococcal group A conjugate vaccine, MenAfriVac, namely the PsATT-004 (phase II) and Pers-004 (phase IV) studies in Ghana, and the PsATT-007 (phase III) and Pers-007 (phase IV) studies in Mali (clinical trial registry numbers ISRCTN82484612, ISRCTN10763234, PACTR201110000328305, and ISRCTN37623829). MenAfriVac was developed by PATH and Serum Institute India Pvt. Ltd. (SIIPL).
This dataset consists of three files:
1. Ghana group data | Tab-delimited text file: Yellow_fever_nAb_Ghana.csv
2. Mali group data | Tab-delimited text file: Yellow_fever_nAb_Mali.csv
3. Data dictionary | PDF file: Yellow_fever_nAb_Data_Dictionary.pdf
Files
Yellow_fever_nAb_Data_Dictionary.pdf
Additional details
Related works
- Is cited by
- Journal article: 10.3205/mbi000557 (DOI)
- Is published in
- Journal article: 10.1016/S1473-3099(19)30323-8 (DOI)
- Is supplemented by
- Software: 10.5281/zenodo.2684193 (DOI)
Funding
- Persistence of (humoral) immunity in children after yellow feveer vacination 206534
- Wellcome Trust
References
- Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO, Mejía JE. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. The Lancet Infectious Diseases 19:1363-1370 (2019). https://doi.org/10.1016/S1473-3099(19)30323-8
Subjects
- Yellow Fever Vaccine
- https://meshb.nlm.nih.gov/record/ui?ui=D022341
- Yellow fever virus
- https://meshb.nlm.nih.gov/record/ui?ui=D015005
- Yellow Fever
- https://meshb.nlm.nih.gov/record/ui?ui=D015004
- Antibodies, Neutralizing
- https://meshb.nlm.nih.gov/record/ui?ui=D057134
- Neutralization Tests
- https://meshb.nlm.nih.gov/record/ui?ui=D009500
- Vaccines, Attenuated
- https://meshb.nlm.nih.gov/record/ui?ui=D014613
- Vaccines
- https://meshb.nlm.nih.gov/record/ui?ui=D014612
- Vaccination
- https://meshb.nlm.nih.gov/record/ui?ui=D014611
- Measles Vaccine
- https://meshb.nlm.nih.gov/record/ui?ui=D008458
- Flavivirus
- https://meshb.nlm.nih.gov/record/ui?ui=D005416
- Immunogenicity, Vaccine
- https://meshb.nlm.nih.gov/record/ui?ui=D000071497
- Infant
- https://meshb.nlm.nih.gov/record/ui?ui=D007223
- Infant Health
- https://meshb.nlm.nih.gov/record/ui?ui=D000068104